Resverlogix Provides Update Regarding Extension of its Filing Calendar
Confirms Annual Filings on SEDAR Confirms Annual Filings on SEDAR
More:
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Author Archives: admin
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) -- NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
See the original post here:
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.
Excerpt from:
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society…
EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Company announcement – No. 48 / 2020
Read more from the original source:
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
The digital press release with multimedia content can be accessed here:
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients…
The digital press release with multimedia content can be accessed here:
Read the original post:
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients...
Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September 17, 2020, on a virtual platform.
Read the original post:
Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational…
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 --SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment with investigational gene therapy, NBIb-1817 (VY-AADC), showed sustained improvement in motor function including greater “On” time without troublesome dyskinesia, reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of medications in patients with Parkinson’s disease. In the PD-1101 study, NBIb-1817 reduced average “Off” time by up to -1.91 hours and improved average “On” time without troublesome dyskinesia by up to +2.23 hours in patients with advanced Parkinson’s disease after three years across three cohorts. In addition, 14 out of 15 patients treated with NBIb-1817 continued to show an improvement in disease staging after three years, as assessed by the modified Hoehn & Yahr scale. These new data, along with two-year data from another open-label Phase Ib trial, PD-1102, were presented today at the MDS Virtual Congress 2020, September 12–16, 2020 (www.mdscongress.org/Congress/Registration.htm).